International
The Morning Science

What science found today

‹
 

Research

TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC

Science · By Shiwei Liu, Zhe Hong, Zhongyuan Wang, Yongqing Zhang, Chenye Jiang, Yuchen Jiang, Runkai Zhang, Zheng Liu, Zhi Shang, Guowen Lin, Zongyuan Hong & Bo Dai ·

The Brief

  • A study in Science Advances reports that TRIM28-mediated SUMOylation of ERG at lysine 389 confers PARP inhibitor resistance in castration-resistant prostate cancer (CRPC).
  • The mechanism works by inhibiting 53BP1 expression.
  • The paper was published in Science Advances, Volume 12, Issue 47, November 2026.

Why it matters

The findings identify a molecular pathway linked to resistance against PARP inhibitors in castration-resistant prostate cancer, which may inform future treatment strategies and biomarker research.

Who’s affected

  • prostate cancer researchers
  • oncologists and clinical researchers working on PARP inhibitors

Science Advances, Volume 12, Issue 47 , November 2026.

Timeline

  1. Study published in Science Advances (Volume 12, Issue 47)

  2. science.org

    TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC

How do you feel about this?

0 Comments

    TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC – The Morning Science